Advertisement

Das Hodgkin-Lymphom beim alten und geriatrischen Patienten

  • Boris Böll
Chapter
Part of the Springer Reference Medizin book series (SRM)

Zusammenfassung

Sofern Komorbidität eine Polychemotherapie nicht verbietet, ist auch bei älteren Hodgkin Patienten in allen Stadien eine Therapie mit kurativem Ziel möglich. In frühen Stadien sind zwei Zyklen ABVD + 20Gy IF-RT meist durchführbar und effektiv. Bei Patienten im intermediären Stadium führt eine Behandlung mit dem Standard vier Zyklen ABVD + 30Gy IF-RT zu einer deutlich erhöhte Rate an Toxizität. Dies gilt umso mehr bei den Patienten in fortgeschrittenen Stadien. Diese erhalten sechs bis acht Zyklen einer Polychemotherapie, wobei bisher kein alternatives Regime gegenüber A(B)VD überlegen ist. Auf Bleomycin muss wegen pulmonaler Toxizität oft teilweise oder ganz verzichtet werden. Unklar ist, welche Patienten palliativ behandelt werden sollten und die Wahl der richtigen Rezidivtherapie. Aktuell werden neue Substanzen wie Brentuximab vedotin oder Checkpoint-Inhibitoren als weniger toxische und wirksame Therapieoption bei älteren Patienten geprüft.

Literatur

  1. Ballova V et al (2005) A prospectively randomized trial carried out by the German Hodgkin study group (GHSG) for elderly patients with advanced Hodgkin’s disease comparing BEACOPP baseline and COPP-ABVD (studyHD9elderly). Ann Oncol 16(1):124–131Google Scholar
  2. Behringer K et al (2014) Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin’s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet 2015, Apr 11 385(9976), S 1–10Google Scholar
  3. Björkholm M, Svedmyr E, Sjöberg J (2011) How we treat elderly patients with Hodgkin lymphoma. Curr Opin Oncol 23(5):421–428CrossRefPubMedGoogle Scholar
  4. Boell B et al (2013) German Hodgkin Study Group phase I trial of doxorubicin, vinblastine, dacarbazine, and lenalidomide (AVD-Rev) for older Hodgkin lymphoma patients. Blood 122(21)Google Scholar
  5. Böll B et al (2011) Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood 118(24):6292–6298CrossRefPubMedGoogle Scholar
  6. Böll B, Görgen H, Fuchs M et al (2013a) ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin study group HD10 and HD11 trials. J Clin Oncol 31(12):1522–1529CrossRefPubMedGoogle Scholar
  7. Böll B, Goergen H, Arndt N et al (2013b) Relapsed Hodgkin lymphoma in older patients: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 31(35):4431–4437CrossRefPubMedGoogle Scholar
  8. Böll B et al (2016) Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood 127(18):2189–2192CrossRefPubMedGoogle Scholar
  9. Canellos GP et al (2004) How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen? J Clin Oncol 22(8):1532–1533CrossRefPubMedGoogle Scholar
  10. Diehl V et al (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med 348(24):2386–2395CrossRefPubMedGoogle Scholar
  11. Eich HT et al (2010) Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin study group HD11 trial. J Clin Oncol 28(27):4199–4206CrossRefPubMedGoogle Scholar
  12. Eichenauer DA et al (2014) Hodgkin’s lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii70–iii75CrossRefPubMedGoogle Scholar
  13. Elias R et al (2016) Immune checkpoint inhibitors in older adults. Curr Oncol Rep. 2016 Aug;18(8):47. S 1–7Google Scholar
  14. Engert A et al (2009) Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 27(27):4548–4554CrossRefPubMedGoogle Scholar
  15. Engert A et al (2010) Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 363(7):640–652CrossRefPubMedGoogle Scholar
  16. Engert A et al (2012) Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet May 12;379(9828):1791–1799Google Scholar
  17. Evens AM, Hong F (2013) How can outcomes be improved for older patients with Hodgkin lymphoma? J Clin Oncol 2013 Apr 20 31(12):1502–1505Google Scholar
  18. Evens AM et al (2012) A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood 119(3):692–695CrossRefPubMedGoogle Scholar
  19. Evens AM et al (2013) The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol 161(1):76–86CrossRefPubMedPubMedCentralGoogle Scholar
  20. Forero-Torres A et al (2015) Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood 126(26):2798–2804CrossRefPubMedPubMedCentralGoogle Scholar
  21. Halbsguth TV et al (2010) Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin study group (GHSG). Blood 116(12):2026–2032CrossRefPubMedGoogle Scholar
  22. Halbsguth TV et al (2011) The unique characteristics and management of patients over 60 years of age with classic Hodgkin lymphoma. Curr Hematol Malig Rep 6(3):164–171CrossRefPubMedGoogle Scholar
  23. Jezeršek Novaković B (2016) Checkpoint inhibitors in Hodgkin’s lymphoma. Eur J Haematol 96(4):335–343CrossRefPubMedGoogle Scholar
  24. Josting A (2005) Salvage radiotherapy in patients with relapsed and refractory Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol 23(7):1522–1529CrossRefPubMedGoogle Scholar
  25. Josting A et al (2002) New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 20(1):221–230PubMedGoogle Scholar
  26. Kolstad A et al (2007) Standard CHOP-21 as first line therapy for elderly patients with Hodgkin’s lymphoma. Leuk Lymphoma 48(3):570–576CrossRefPubMedGoogle Scholar
  27. Landgren O et al (2003) Hodgkin’s lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica 88(4):438–444PubMedGoogle Scholar
  28. Levis A et al (2004) VEPEMB in elderly Hodgkin’s lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. Ann Oncol 15(1):123–128CrossRefPubMedGoogle Scholar
  29. Levis A et al (2007) ABVD versus VEPEMB in elderly Hodgkin’s lymphoma patients. Blood 110(11):2322Google Scholar
  30. Martin WG (2005) Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol 23(30):7614–7620CrossRefPubMedGoogle Scholar
  31. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012 Mar 22;12(4):252–264. S 1–13Google Scholar
  32. Proctor SJ, Wilkinson J (2007) A web-based study concept designed to progress clinical research for „orphan“ disease areas in haematological oncology in the elderly: the SHIELD programme. Crit Rev Oncol Hematol 61(1):79–83CrossRefPubMedGoogle Scholar
  33. Proctor SJ et al (2002) Hodgkin’s disease in the elderly: current status and future directions. Ann Oncol 13(Suppl 1):133–137CrossRefPubMedGoogle Scholar
  34. Proctor SJ et al (2012) Prospective evaluation of treatment outcome in 175 patients with Hodgkin lymphoma (HL) aged sixty years or over: the SHIELD study. Blood 119(25):6005–6015CrossRefPubMedGoogle Scholar
  35. Puig N et al (2011) High-dose chemotherapy and auto-SCT in elderly patients with Hodgkin’s lymphoma. BMT 46(10):1339–1344Google Scholar
  36. Radford J et al (2015) Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med 372(17):1598–1607CrossRefPubMedGoogle Scholar
  37. Raemaekers JMM et al (2014) Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 32(12):1188–1194CrossRefPubMedGoogle Scholar
  38. Santoro A et al (2000) Gemcitabine in the treatment of refractory Hodgkin’s disease: results of a multicenter phase II study. J Clin Oncol 18(13):2615–2619CrossRefPubMedGoogle Scholar
  39. Sjöberg J et al (2012) Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973–2009. Blood 119(4)Google Scholar
  40. Stamatoullas A et al (2015) Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol 170(2):179–184CrossRefPubMedGoogle Scholar
  41. Tresckow B von et al (2012) Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin study group HD14 trial. J Clin Oncol 30(9):907–913Google Scholar
  42. Weekes CD et al (2002) Hodgkin’s disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen. J Clin Oncol 20(4):1087–1093PubMedGoogle Scholar
  43. Younes A et al (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 30(18):2183–2189CrossRefPubMedPubMedCentralGoogle Scholar
  44. Zallio F et al (2016) Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL). Br J Haematol 172(6):879–888CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Deutsche Hodgkin Studiengruppe (GHSG) Klinik I für Innere Medizin-Hämatologie-Onkologie, Internistische IntensivmedizinKölnDeutschland

Section editors and affiliations

  • Ulrich Wedding
    • 1
  1. 1.Abteilung für PalliativmedizinUniversitätsklinikum Jena, Klinik für Innere Medizin IIJenaDeutschland

Personalised recommendations